GAM
ALXN

Grandview Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Grandview Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8
Closed -$1K – 528
2021
Q1 		$1K Buy
+8
New +$1.24K ﹤0.01% 507

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HBK Investments
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Davidson Kempner Capital Management
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Grandview Asset Management's ALXN Position: Q2 2021 in Review

Grandview Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 8 shares — an estimated $1K sold.

Grandview Asset Management first reported a position in ALXN in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Grandview Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Grandview Asset Management sold 8 Alexion Pharmaceuticals shares in Q2 2021, an estimated $1K.
  • Grandview Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Grandview Asset Management's Alexion Pharmaceuticals position peaked at $1K in Q1 2021.
  • 710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Grandview Asset Management's 13F filing for Q2 2021, filed 21 Jul 2021.